Study on the Effect of the OMNi-BiOTiC4 Hetox Multistrain Probiotic to Improve Healing and Reduce Pain After Neurosurgery

What this Trial Is About

Researchers are evaluating the effect of a multistrain probiotic called OMNi-BiOTiC4 Hetox on healing, pain management, and postsurgical complications following neurosurgery. This randomized controlled trial aims to determine if the probiotic improves patient-reported disability after neurosurgery by comparing it to a placebo. The study is led by University Maribor and focuses on adults who have undergone neurosurgery for conditions like disc herniation, stenosis, or spinal instability. Participants will be randomly assigned to receive either the OMNi-BiOTiC4 Hetox probiotic or a placebo. The probiotic contains several bacterial strains including Lacticaseibacillus casei W56, Lactobacillus acidophilus W37, and others, along with various supportive substances. The study involves a supplementation period lasting 4 weeks during which participants take the assigned dietary supplement. During the study, researchers will measure changes in disability using the Oswestry Disability Index ODI at 3 months after starting supplementation. Participants will undergo assessments and follow-up visits to monitor healing progress and any postsurgical complications. The trial includes safety monitoring to ensure no adverse reactions to the probiotic and has a total participation period covering at least 3 months after supplementation begins.

Effect of Probiotics After Neurosurgery